Logo

MediGene Raises $26M In Private Placement

Nov 21, 1998
Premium

MUNICH--MediGene, a late-stage biopharmaceutical company developing drugs and technologies against disease targets in the areas of cancer and cardiology, completed a $25.7 million private placement involving institutional and private investors last week. The financing includes options for convertible loans of $2.3 million and a long-term loan of $6.6 million. Participants included Deutsche Bank, Dresdner Bank, Bankhaus Vontobel, Atlas Venture, Dieckell GmbH, Merifin Capital, and TBG der Deutschen Ausgleichsbank. Participating existing shareholders included Techno Venture Management, Star Ventures, Alpinvest, and a private investor group.

Filed under

Informatics
Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.